Filed
Pursuant to Rule 424(b)(5)
Reg. No. 333-280680
PROSPECTUS
Up to $7,350,000 of Shares
of Common Stock
We have entered into an At Market Issuance
Sales Agreement, dated July 3, 2024 (the “Sales Agreement”), with Chardan Capital Markets, LLC (“Chardan”)
and Craig-Hallum Capital Group LLC (“Craig-Hallum”) relating to the sale of shares of our common stock, par value $0.001
per share (the “Common Stock”), having an aggregate offering price of up to $7,350,000 from time to time through or to
Chardan and Craig-Hallum, acting as sales agents. Chardan and Craig-Hallum are collectively referred to as the “Sales
Agents” and each individually referred as a “Sales Agent.” Under the terms of the Sales Agreement, we may also
sell shares of Common Stock to a Sales Agent as principal for its own account.
Sales of shares of our Common Stock, if any, under
this prospectus will be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated
under the Securities Act of 1933, as amended (the “Securities Act”). The Sales Agents are not required to sell any specific
amount, but will act as sales agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices,
on mutually agreed terms between the Sales Agents and us. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement.
As sales agents, Chardan and Craig-Hallum are
entitled to compensation at a fixed commission rate equal to 3.0% of the gross proceeds of each sale of shares of our Common Stock under
the Sales Agreement. In connection with the sale of our shares of Common Stock on our behalf, each of the Sales Agents will be deemed
to be an “underwriter” within the meaning of the Securities Act and the compensation of the Sales Agents will be deemed to
be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Sales Agents with respect
to certain liabilities, including liabilities under the Securities Act.
Our Common Stock is listed on the NYSE American
LLC under the symbol “IBIO.” On July 19, 2024, the last reported sale price of our Common Stock on the NYSE American LLC
was $2.15 per share.
As of the date of this prospectus, the aggregate
market value of our outstanding Common Stock held by non-affiliates is approximately $22,134,382, which is calculated based on 8,612,600
shares of our outstanding Common Stock held by non-affiliates and a price of $2.57 per share, the closing price of our Common Stock on
June 13, 2024, which is the highest closing sale price of our Common Stock on the NYSE American LLC within the prior 60 days of this prospectus.
During the prior twelve calendar month period that ends on and includes the date hereof, we have not offered or sold any shares of our
Common Stock pursuant to General Instruction I.B.6 to Form S-3.
Investing in our Common Stock involves
a high degree of risk. Before making an investment decision, please read the information under the heading “Risk Factors”
beginning on page S-6 of this prospectus supplement and in the documents incorporated by reference into this prospectus.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.
Chardan Capital Markets, LLC | |
Craig-Hallum Capital Group LLC |
The date of this prospectus is August
6, 2024
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus relates to part of a registration
statement on Form S-3 that we have filed with the Securities and Exchange Commission (the “SEC”) utilizing a “shelf”
registration process. Under this shelf registration process, we may sell any combination of the securities described in our base prospectus
included in the shelf registration statement in one or more offerings up to a total aggregate offering price of $150,000,000. The $7,350,000
of shares of Common Stock that may be offered, issued and sold under this prospectus is included in the $150,000,000 of securities that
may be offered, issued and sold by us pursuant to our shelf registration statement. In connection with such offers and when accompanied
by the base prospectus included in the registration statement of which this prospectus is a part, this prospectus will be deemed a prospectus
supplement to such base prospectus.
This prospectus relates to the offering of our
shares of Common Stock. Before buying any of our shares of Common Stock that we are offering, we urge you to carefully read this prospectus,
together with the information incorporated by reference as described under the headings “Where You Can Find More Information”
and “Incorporation of Certain Information by Reference” in this prospectus. These documents contain important information
that you should consider when making your investment decision.
This prospectus describes the terms of this offering
of our shares of Common Stock and also adds to and updates information contained in the documents incorporated by reference into this
prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information
contained in any document incorporated by reference into this prospectus that was filed with the SEC before the date of this prospectus,
on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with
a statement in another document having a later date (for example, a document incorporated by reference into this prospectus) the statement
in the document having the later date modifies or supersedes the earlier statement.
You should rely only on the information contained
in or incorporated by reference in this prospectus and in any free writing prospectus that we have authorized for use in connection with
this offering. We have not, and the Sales Agents have not, authorized anyone to provide you with different information. If anyone provides
you with different or inconsistent information, you should not rely on it. We are not, and the Sales Agents are not, making an offer to
sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in
this prospectus, the documents incorporated by reference in this prospectus, and in any free writing prospectus that we have authorized
for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition,
results of operations and prospects may have changed since those dates. You should carefully read this prospectus, the documents incorporated
by reference in this prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in
their entirety before making an investment decision.
We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus
were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among
the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should
not be relied on as accurately representing the current state of our affairs.
This prospectus contains and incorporates by reference
market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information.
Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have
not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented
in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject
to change based on various factors, including those discussed under the heading “Risk Factors” in this prospectus and under
similar headings in the other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place
undue reliance on this information.
Except as otherwise indicated herein or as the
context otherwise requires, references in this prospectus to “iBio,” the “Company,” “we,” “us,”
“our” and similar references refer to iBio, Inc., an entity incorporated under the laws of the State of Delaware,
and where appropriate our consolidated subsidiaries.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus, including the documents that
we incorporate by reference herein, may contain, forward-looking statements within the meaning of Section 27A of the Securities Act
and Section 21E of the Securities Exchange Act of 1934, as amended (“the Exchange Act”), including statements regarding
our future financial condition, business strategy and plans and objectives of management for future operations. Forward-looking statements
include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as
“believe,” “will,” “may,” “estimate,” “continue,” “anticipate,”
“intend,” “should,” “plan,” “might,” “approximately,” “expect,”
“predict,” “could,” “potentially” or the negative of these terms or other similar expressions. Forward-looking
statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations.
Discussions containing these forward-looking statements
may be found, among other places, in the sections entitled “Business,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” contained in the documents incorporated by reference in
this prospectus, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, as well as any
amendments thereto.
These statements relate to future events or our
future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results,
levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements.
We discuss in greater detail, and incorporate by reference into this prospectus in their entirety, many of these risks and uncertainties
under the section entitled “Risk Factors” included in our most recent Annual Report on Form 10-K and our Quarterly Reports
on Form 10-Q, as well as any amendments thereto, filed with the SEC, which are incorporated by reference into this prospectus. Additional
factors are discussed under the section entitled “Risk Factors” in this prospectus and any free writing prospectus and under
similar headings in the other documents that are incorporated by reference into this prospectus. These statements reflect our current
views with respect to future events and are based on assumptions and subject to risks and uncertainties. New risks and uncertainties arise
from time to time, and it is impossible for us to predict these events or how they may affect us. We undertake no obligation to revise
or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and
uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement.
PROSPECTUS SUMMARY
The following summary highlights information
contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the information that may be important
to purchasers of our securities. This summary is not intended to be complete and does not contain all of the information that you should
consider before deciding to invest in our securities. You should read this entire prospectus carefully, especially the “Risk Factors”
section beginning on page S-6 and other documents or information included or incorporated by reference in this prospectus before
making an investment decision.
Overview
iBio, Inc. (“iBio,”
“we,” “us,” or “our”) is a pre-clinical pioneering biotechnology company at the intersection of AI
and biologics, committed to reshaping the landscape of discovery. Our core mission is to harness the potential of AI and machine learning
to unveil elusive biologics that stand out and have evaded other scientists. Through our innovative platform, we champion a culture of
innovation by identifying novel targets, forging strategic collaborations to enhance efficiency, diversify pipelines, and with the goal
of accelerating preclinical processes. During the past few years, we have focused on the development
of vaccines and therapeutics for commercialization. Our current focus is immune-oncology therapeutics. Our current vaccines and
therapeutics being developed are all in preclinical development and we. have not completed any clinical trials for any vaccine or therapeutic
protein product candidate produced using iBio technology and there is a risk that we will be unsuccessful in developing or commercializing
any product candidates.
Our EngageTx™
technology enables us to target bi-specific molecules. Our pre-clinical data demonstrates our ability to generate multiple hits creating
sequence diversity and promoting Human-Cyno cross reactivity while mitigating cytokine release, our goal is to enhance agility and bolster
preclinical safety assessments.
Our strategic approach
to fulfilling our mission is outlined as follows:
| ● | Elevate Epitope Discovery:
Our patented AI-engine is being used to uncoveri "hard to develop" molecules. Our
epitope engine allows us to target select regions of a protein with the goal of , removing
the lengthy trial and error out of mAb discovery. This capability is being used to generate
preclinical data aimed at improving the probability of successfully determining which candidates
to further develop, which would reduce costs and time commonly caused by having an iterative
process. Our epitope engine is engineered to match its target, refined for stability and
optimized for water solubility, allowing us to identify new drug candidates that have failed
or have been abandoned due to their complexity. |
| ● | Capital Efficient Business Approach: Our strategic business approach is structured around the following
pillars of value creation: |
| o | Strategic Partnerships: We are leveraging our platform and pipeline by forming strategic partnerships.
Our aim is to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration
of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, a rich array of fast follower
molecules within our pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects.
By tapping into our platform, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to
biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency. |
| o | Tech Licensing in Diverse Therapeutic Areas: In pursuit of adding value, we are exploring partnerships
in diverse therapeutic domains such as CNS or vaccines. Our intention is to license the AI tech stack, extending its benefits to our partners
and amplifying its biological impact and insights. This strategic approach enables us to capitalize on the value of our meticulously curated
data while empowering collaborations and innovations. |
| o | Developing and Advancing Our In-house Programs Cost Effectively: Clinical advancement is crucial
for drug discovery. We are actively looking for opportunities to progress our internal pre-clinical programs, with a focal point on oncology,
obesity, and cardiometabolic diseases, steadily reinforcing our pre-clinical pipeline. |
| ● | Unwavering Investment in Advancing the Platform: We maintain an unwavering commitment to invest
in our platform, continually unlocking the potential of biology through AI and machine learning – the pinnacle of being on the forefront
of machine learning advancing algorithms and models in order to improve its predictive power and reduce the time it takes to find a viable
molecule. |
In essence, we are sculpting
a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating
innovation, and propelling the advancement of science.
|
|
|
|
THE OFFERING |
|
|
|
|
|
|
Issuer |
iBio, Inc. |
|
|
|
|
|
|
Common stock to be offered by us
pursuant to this prospectus |
Up
to 3,418,604 shares of our Common Stock having an aggregate offering price of up to approximately $7.35 million at an assumed offering
price of $2.15 per share, which was the last reported sale price of our Common Stock on the NYSE American on July 19, 2024. |
|
|
|
|
|
|
Common stock to be outstanding
after the offering |
Up
to 12,042,289 (as more fully described in the notes following this table), assuming sales of approximately $7.35 million shares of
our Common Stock, or 3,418,604 shares of our Common Stock in this offering at an assumed offering price of $2.15 per share, which
was the last reported sale price of our Common Stock on the NYSE American on July 19, 2024. The actual number of shares issued will
vary depending on the sales price under this offering.(1) |
|
|
|
|
|
|
Manner of offering |
“At
the market offering” that may be made from time to time for our Common Stock in the United States through Chardan and Craig-Hallum,
as Sales Agents or to Chardan or Craig-Hallum, as principal. See the section entitled “Plan of Distribution.” |
|
|
|
|
|
|
Use of proceeds |
We
currently intend to use the net proceeds from this offering for working capital and general corporate purposes, including, including,
to acquire, license or invest in assets, businesses, technologies, product candidates or other intellectual property and to repurchase
securities. See “Use of Proceeds.” |
|
|
|
|
|
|
Risk factors |
You
should read the “Risk Factors” section of this prospectus and in the documents incorporated by reference in this
prospectus for a discussion of factors to consider before deciding to purchase shares of our Common Stock. |
|
|
|
|
|
|
NYSE American
Trading Symbol |
IBIO |
|
|
Unless we indicate otherwise,
all information in this prospectus is based on 8,623,685 shares outstanding as of July 19, 2024. The number of shares outstanding
as used throughout this prospectus, unless otherwise indicated, excludes:
● 910,044
shares of Common Stock issuable upon the exercise of stock options outstanding at a weighted average exercise price of $6.45 per share;
● 12,125,198
shares of Common Stock issuable upon the exercise of warrants outstanding at a weighted average exercise price of $1.95 per share;
● 36,620
shares of Common Stock issuable upon the vesting of restricted stock units; and
● 251,600
shares of Common Stock reserved for future issuance under the 2023 Omnibus Equity Incentive Plan. |
|
|
|
|
SELECTED
FINANCIAL DATA REFLECTING THE 2023 REVERSE STOCK SPLIT
On
November 29, 2023, we effected a 1-for-20 reverse stock split of our Common Stock (the “2023 Reverse Stock Split”).
The total number of outstanding shares of Common Stock was reduced from approximately 28,100,733
to approximately 1,405,036 shares. The par value per common share remained unchanged.
The audited consolidated financial statements of the Company included in the Annual Report on Form 10-K for the year ended
June 30, 2023, and the unaudited condensed consolidated financial statements included in our Quarterly Report on Form 10-Q for
the period ended March 31, 2024, which are incorporated by reference into this prospectus are presented without giving effect to
the 2023 Reverse Stock Split.
The
following selected financial data has been derived from our audited consolidated financial statements included in our Annual Report on
Form 10-K filed with the SEC on September 27, 2023, and our unaudited condensed consolidated financial statements included
in our Quarterly Report on Form 10-Q filed with the SEC on May 13, 2024, as adjusted to reflect the 2023 Reverse Stock Split
for all periods presented. Our historical results are not indicative of the results that may be expected in the future and results of
interim periods are not indicative of the results for the entire year.
The
following table presents selected share information reflecting the 2023 Reverse Stock Split for the years ended June 30, 2023 and 2022:
| |
Year Ended
June 30, | |
| |
2023 | | |
2022 | |
Weighted-average common shares outstanding
- pre-split | |
| 12,244,969 | | |
| 8,721,324 | |
Weighted-average common shares outstanding - post-split | |
| 612,248 | | |
| 436,066 | |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - pre-split | |
$ | (2.39 | ) | |
$ | (3.39 | ) |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - post-split | |
$ | (47.87 | ) | |
$ | (67.88 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - pre-split | |
$ | (2.92 | ) | |
$ | (2.39 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - post-split | |
$ | (58.31 | ) | |
$ | (47.68 | ) |
Basic and diluted net loss per share attributable to common
stockholders - pre-split | |
$ | (5.31 | ) | |
$ | (5.78 | ) |
Basic and diluted net loss per share attributable to common
stockholders - post-split | |
$ | (106.18 | ) | |
$ | (115.56 | ) |
The
following table presents selected share information reflecting the 2023 Reverse Stock Split for the three months ended March 31, 2024
and 2023:
| |
2024 | | |
2023 | |
Weighted-average common shares outstanding
- pre-split | |
| | | |
| 13,184,219 | |
Weighted-average common shares outstanding - post-split | |
| 3,713,103 | | |
| 659,210 | |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - pre-split | |
| | | |
$ | (0.47 | ) |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - post-split | |
$ | (0.71 | ) | |
$ | (9.53 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - pre-split | |
| | | |
$ | (0.08 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - post-split | |
$ | (0.14 | ) | |
$ | (1.54 | ) |
Basic and diluted net loss per share attributable to common
stockholders - pre-split | |
| | | |
$ | (0.55 | ) |
Basic and diluted net loss per share attributable to common
stockholders - post-split | |
$ | (0.85 | ) | |
$ | (11.07 | ) |
The
following table presents selected share information reflecting the 2023 Reverse Stock Split for the nine months ended March 31, 2024
and 2023:
| |
2024 | | |
2023 | |
Weighted-average common shares outstanding
- pre-split | |
| | | |
| 10,592,240 | |
Weighted-average common shares outstanding - post-split | |
| 2,247,250 | | |
| 529,611 | |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - pre-split | |
| | | |
$ | (2.30 | ) |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - post-split | |
$ | (5.43 | ) | |
$ | (46.00 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - pre-split | |
| | | |
$ | (3.27 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - post-split | |
$ | (2.19 | ) | |
$ | (65.28 | ) |
Basic and diluted net loss per share attributable to common
stockholders - pre-split | |
| | | |
$ | (5.57 | ) |
Basic and diluted net loss per share attributable to common
stockholders - post-split | |
$ | (7.62 | ) | |
$ | (111.28 | ) |
RISK FACTORS
Investing in our Common Stock involves a high
degree of risk, and you should be able to bear the complete loss of your investment. You should consider carefully the risks described
below and those described under the section captioned “Risk Factors” contained in our Annual Report on Form 10-K for the year ended June 30, 2023, any subsequent Annual Reports on Form 10-K, any subsequent Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K, and all other information contained or incorporated by reference into this
prospectus and documents incorporated by reference into this prospectus before deciding whether to purchase any of the Common Stock being
offered under this prospectus. If any of the risks actually occur, our business, consolidated financial condition or results of operations
could be adversely affected. In such case, the trading price of our Common Stock could decline and you could lose all or part of your
investment. Our actual results could differ materially from those anticipated in the forward-looking statements made throughout this prospectus
as a result of different factors, including the risks we face described below. Unless we have indicated otherwise or the context otherwise
requires, references in this prospectus or the documents incorporated by reference herein and therein to the “Company,” “iBio,”
“we,” “us” and “our” refer to iBio, Inc.
Risks Related to this Offering
Our management will have broad discretion
over the use of proceeds from this offering and may not use the proceeds effectively.
Our management will have broad discretion over
the use of proceeds from this offering. We intend to use the net proceeds from this offering, if any, for working capital and general
corporate purposes, including, to acquire, license or invest in assets, businesses, technologies, product candidates or other intellectual
property and to repurchase securities. Our management will have considerable discretion in the application of the net proceeds, and you
will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. The net
proceeds, if any, may be used for corporate purposes that do not improve our operating results or enhance the value of our Common Stock.
The failure of our management to use these funds effectively could have a material adverse effect on our business and cause the market
price of our Common Stock to decline. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade,
interest-bearing instruments and U.S. government securities. These investments may not yield a favorable return to our stockholders.
If you purchase shares of our Common Stock
sold in this offering, you will experience immediate and substantial dilution in the net tangible book value of your shares. In addition,
we may issue additional equity or convertible debt securities in the future, which may result in additional dilution to investors.
The price per share of our Common Stock being
offered may be higher than the net tangible book value per share of our outstanding Common Stock prior to this offering. Assuming that
an aggregate of 3,418,604 shares of our Common Stock are sold at a price of $2.15 per share, the last reported sale price of our Common
Stock on the NYSE American on July 19, 2024, new investors in this offering will incur immediate dilution of $0.38 per share, representing
the difference between our as adjusted net tangible book value per share as of March 31, 2024 after giving effect to this offering and
the assumed price. For a more detailed discussion of the foregoing, see the section entitled “Dilution” elsewhere in this
prospectus. To the extent that our outstanding stock options or warrants are exercised, there will be further dilution to new investors.
Our need for future financing may result
in the issuance of additional securities which will cause investors to experience dilution.
Our cash requirements may vary from those now
planned depending upon numerous factors. We expect to require additional capital until our operations generate sufficient revenue to cover
our expenses. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. There are
no other commitments by any person for future financing. Our securities may be offered to other investors at a price lower than the price
per share offered to current stockholders, or upon terms which may be deemed more favorable than those offered to current stockholders.
In addition, the issuance of securities in any future financing may dilute an investor’s equity ownership and have the effect of
depressing the market price for our securities. Moreover, we may issue derivative securities, including options and/or warrants, from
time to time, to procure qualified personnel or for other business reasons. The issuance of any such derivative securities, which is at
the discretion of our Board of Directors, may further dilute the equity ownership of our stockholders.
We may sell shares or other securities in any
other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing
shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional
shares of our Common Stock, or securities convertible or exchangeable into Common Stock, in future transactions may be higher or lower
than the price per share paid by investors in this offering. No assurance can be given as to our ability to procure additional financing,
if required, and on terms deemed favorable to us. To the extent additional capital is required and cannot be raised successfully, we may
then have to limit our then current operations and/or may have to curtail certain, if not all, of our business objectives and plans.
We have additional securities available
for issuance, which, if issued, could adversely affect the rights of the holders of our Common Stock.
Our Certificate of Incorporation, as amended (the
“Certificate of Incorporation”), authorizes the issuance of 275,000,000 shares of our Common Stock and 1,000,000 shares of
preferred stock. In certain circumstances, shares of our Common Stock, as well as the awards available for issuance under our equity incentive
plans, can be issued by our Board of Directors, without stockholder approval. Any future issuances of such stock would further dilute
the percentage ownership of us held by holders of our Common Stock and preferred stock. In addition, the issuance of certain securities,
including pursuant to the terms of our stockholder rights plan, may be used as an “anti-takeover” device without further action
on the part of our stockholders, and may adversely affect the holders of the Common Stock.
Because we do not intend to declare cash
dividends on our shares of Common Stock in the foreseeable future, stockholders must rely on appreciation of the value of our Common Stock
for any return on their investment.
As stated above, we have never declared or paid
cash dividends on our Common Stock. We currently anticipate that we will retain future earnings for the development, operation and expansion
of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, we expect that only
appreciation of the price of our Common Stock, if any, will provide a return to investors in this offering for the foreseeable future.
Resales of our Common Stock in the public
market during this offering by our stockholders may cause the market price of our Common Stock to fall.
We may issue shares of our Common Stock from time
to time in connection with this offering. This issuance from time to time of these new shares of our Common Stock, or our ability to issue
these shares of our Common Stock in this offering, could result in resales of our Common Stock by our current stockholders concerned about
the potential dilution of their holdings. In turn, these resales could have the effect of depressing the market price for our Common Stock.
The actual number of shares we will issue
under the Sales Agreement, at any one time or in total, is uncertain.
Subject to certain limitations in the Sales Agreement
with the Sales Agents and compliance with applicable law, we have the discretion to deliver placement notices to the Sales Agents at any
time throughout the term of the Sales Agreement. The number of shares that are sold by the Sales Agents after delivering a placement notice
will fluctuate based on the market price of the Common Stock during the sales period and limits we set with the Sales Agents.
The shares of Common Stock offered under
this prospectus and documents incorporated by reference into this prospectus may be sold in “at the market offerings,” and
investors who buy shares at different times will likely pay different prices.
Investors who purchase shares under this prospectus
and documents incorporated by reference into this prospectus at different times will likely pay different prices, and so may experience
different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers
of shares sold, and there is no minimum or maximum sales price. Investors may experience declines in the value of their shares as a result
of share sales made at prices lower than the prices they paid.
USE OF PROCEEDS
We may issue and sell shares of our Common Stock
having aggregate gross proceeds of up to $7,350,000 from time to time under this prospectus and the documents incorporated by reference
herein and therein. Because there is no minimum offering amount required as a condition to close this offering, the actual total offering
amount, commissions and proceeds to us, if any, are not determinable at this time. The amount of proceeds from this offering will depend
upon the number of shares of our Common Stock sold and the market price at which they are sold. There can be no assurance that we will
be able to sell any shares of our Common Stock under or fully utilize the Sales Agreement with Chardan and Craig-Hallum as a source of
financing.
We intend to use the net proceeds, if any, from
the sales of shares of our Common Stock offered by this prospectus for working capital and general corporate purposes, including, to acquire,
license or invest in assets, businesses, technologies, product candidates or other intellectual property and to repurchase securities.
We have broad discretion in determining how the proceeds of this offering will be used, and our discretion is not limited by the aforementioned
possible uses. Our Board of Directors believes the flexibility in application of the net proceeds is prudent.
As of the date of this prospectus, we cannot specify
with certainty all of the particular uses for the net proceeds to be received from this offering. The amounts and timing of our actual
expenditures will depend on numerous factors including our operating costs and the amount of funding, if any, received from grants. Accordingly,
our management will have broad discretion in the application of the net proceeds, and investors will be relying on the judgment of management
regarding the application of the net proceeds from the offering. We may find it necessary or advisable to reallocate the net proceeds
of this offering; however, any such reallocation would be substantially limited to the categories set forth above as we do not intend
to use the net proceeds for other purposes. Pending such uses set forth above, we plan to invest the net proceeds in government securities
and other short-term investment grade, marketable securities.
DIVIDEND POLICY
We have never declared or paid any cash dividends
on our capital stock and we do not currently intend to pay any cash dividends on our Common Stock in the foreseeable future. We expect
to retain all available funds and future earnings, if any, to fund the development and growth of our business. Any future determination
to pay dividends, if any, on our Common Stock will be at the discretion of our Board of Directors and will depend on, among other factors,
our results of operations, financial condition, capital requirements and contractual restrictions.
DILUTION
Our net tangible book
value as of March 31, 2024 was approximately $19.5 million, or $2.29 per share. Net tangible book value per share is determined
by dividing our total tangible assets, less total liabilities, by the number of shares of our Common Stock outstanding as of March 31,
2024. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers
of shares of Common Stock in this offering and the net tangible book value per share of our Common Stock immediately after this offering.
After giving effect to: (i) a reduction of
cash of approximately $1.5 million to pay closing costs and real estate taxes owed on the Bryan, Texas facility; (ii) a reduction of
assets held for sale of approximately $15 million, (iii) a reduction in liability of approximately $13.2 million upon the full satisfaction
of the obligations of iBio CDMO and us pursuant to the Credit Agreement; (iv) a reduction in liabilities of approximately $1.9 million
related to the cancellation of our land lease in conjunction with the sale of the Bryan, Texas facility; (v) a reduction in liabilities
of approximately $0.8 million related to real estate taxes paid on the Bryan, Texas facility; (vi) an increase in liabilities related
to the warrant issued to Woodforest for the deficiency on funds owed the related to the Bryan, Texas facility sale; and (vii) our issuance
of 106,236 shares of Common Stock upon the exercise of warrants and vesting of RSUs subsequent to March 31, 2024, our pro forma net tangible
book value as of March 31, 2024 would have been approximately $14.4 million, or $1.67 per share.
After giving effect
to the pro forma adjustments above and the sale of 3,418,604 shares of our Common Stock in this offering at an assumed offering price
of $2.15 per share, which is the closing price of our Common Stock on the NYSE American on July 19, 2024, and after deducting the Sales
Agents fees and estimated offering expenses payable by us, our pro forma, as adjusted net tangible book value as of March 31, 2024
would have been approximately $21.3 million, or $1.77 per share. This represents an immediate dilution of $0.38 per share
to new investors purchasing securities in this offering. The following table illustrates this per share dilution:
Assumed
public offering price per share | |
$ | 2.15 | |
Net tangible
book value per share as of March 31, 2024 | |
$ | 2.29 | |
Increase
in net tangible book value per share attributable to this offering | |
$ | 0.08 | |
Pro
forma, as adjusted net tangible book value per share as of March 31, 2024, after giving effect to this offering | |
$ | 1.77 | |
Dilution
per share to new investors purchasing our Common Stock in this offering | |
$ | 0.38 | |
The above discussion and table is based on
8,517,449 shares of our Common Stock outstanding as of March 31, 2024, as adjusted for the adjustments set forth above and excludes
as of March 31, 2024:
● 32,644
shares of Common Stock issuable upon the exercise of stock options outstanding at a weighted average exercise price of $144.90 per share;
● 10,564,628
shares of Common Stock issuable upon the exercise of warrants outstanding at a weighted average exercise price of $2.24 per share;
● 61,365
shares of Common Stock issuable upon the vesting of restricted stock units; and
● 1,121,200
shares of Common Stock reserved for future issuance under the 2023 Omnibus Equity Incentive Plan.
The above illustration of dilution per share to
investors participating in this offering assumes no exercise of outstanding options to purchase our Common Stock or outstanding warrants
to purchase shares of our Common Stock. To the extent that any of these outstanding options or warrants are exercised or we issue additional
shares under our equity incentive plans, there will be further dilution to new investors. In addition, we may choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these
securities could result in further dilution to our stockholders.
PLAN OF DISTRIBUTION
On July 3, 2024, we entered into an At
Market Issuance Sales Agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC, which we refer to as the
“Sales Agreement,” which provides for the issuance and sale by us of shares of our Common Stock having an aggregate
offering price of up to $7.35 million from time to time through Chardan and Craig-Hallum, acting as Sales Agents. Under the terms of
the Sales Agreement, we may also sell shares to a Sales Agent as principal for its own account.
Upon instructions from us, a Sales Agent will
use commercially reasonable efforts, consistent with its normal sales and trading practices and applicable law, to sell shares of our
Common Stock under the Sales Agreement pursuant to this prospectus. Sales of shares of Common Stock, if any, pursuant to this prospectus
may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 under the Securities
Act, including, without limitation, sales made directly on or through the NYSE American, the existing trading market for the Common Stock,
on any other existing trading market for our Common Stock, or sales made to or through a market maker other than on an exchange, at market
prices prevailing at the time of sale or at prices related to such prevailing market prices or in privately negotiated transactions. If
we and a Sales Agent agree on any method of distribution other than sales of shares of our Common Stock into the NYSE American or another
existing trading market in the United States at market prices, we will file a prospectus supplement providing all information about such
offering as required by Rule 424(b) under the Securities Act. To the extent required by Regulation M, no Sales Agent will engage in any
transactions that stabilize our Common Stock while the offering is ongoing under this prospectus.
Under the Sales Agreement between us and the Sales
Agents, we will instruct a Sales Agent in a sales notice as to the maximum amount of shares of our Common Stock to be sold by the Sales
Agent daily, and the minimum price per share at which such shares may be sold. Subject to the conditions of the Sales Agreement, a Sales
Agent will use its commercially reasonable efforts to solicit purchases on a particular day of all shares designated for sale by us on
that day. The gross sales price of the shares sold will be the market price for shares of our Common Stock sold by the Sales Agent on
the trading market at the time of sale of the shares. We or a Sales Agent may suspend the offering of our Common Stock upon proper notice
and subject to certain other conditions. The obligation of a Sales Agent under the Sales Agreement to sell our Common Stock pursuant to
a sales notice is subject to a number of conditions.
The Sales Agent will provide written confirmation
to us following the close of trading on the NYSE American following each day in which shares of our Common Stock are sold under the Sales
Agreement. Each confirmation will include the number of shares sold on the day, the aggregate gross sales proceeds, the net proceeds to
us and the compensation payable by us to the Sales Agent with respect to the sales.
We will pay the Sales Agents a commission for
their services in acting as our agents in the sale of our Common Stock. The compensation payable to the Sales Agents for sales of shares
of our Common Stock with respect to which the Sales Agents act as agents shall be equal to 3.0% of the gross sales price of those shares.
There is no guarantee that there will be any sales of our Common Stock under this prospectus and actual sales, if any, of our Common Stock
under this prospectus may result in gross proceeds to us of less than $7.35 million, exclusive of any sales agent compensation or other
offering fees and expenses.
Settlement for sales of shares of our Common Stock
will occur on the first business day following the date on which any sales are made. There is no arrangement for funds to be received
in an escrow, trust or similar arrangement.
In connection with the sale of shares of our Common
Stock on our behalf, a Sales Agent may be deemed to be an “underwriter” within the meaning of the Securities Act, and the
compensation of the Sales Agent may be deemed to be underwriting commissions or discounts. We have also agreed to reimburse the Sales
Agents for certain specified expenses, including the fees and disbursements of its legal counsel in an amount not to exceed $75,000 in
connection with the Sales Agreement, plus $5,000 per quarter so long as the Sales Agreement remains in effect and the Sales Agents perform
standard quarterly due diligence and $25,000 in connection with any filing of an additional prospectus supplement. We have agreed to provide
indemnification and contribution to the Sales Agents with respect to certain civil liabilities, including liabilities under the Securities
Act and the Exchange Act.
We estimate that the total expenses of the offering
payable by us, excluding commissions payable to the Sales Agents under the Sales Agreement, will be approximately $250,000.
The offering of shares of our Common Stock pursuant
to the Sales Agreement will terminate upon the earlier of (1) the sale of all of our Common Stock provided for in this prospectus, or
(2) the termination of the Sales Agreement. The Sales Agreement will automatically terminate upon the issuance and sale of all of the
shares of Common Stock pursuant to the Sales Agreement and may be terminated by us at any time in our sole discretion by giving four
days’ written notice to the Sales Agents, or by either of the Sales Agents at any time in its sole discretion by giving four days’
written notice to us, but solely with respect to such Sales Agent’s participation in the offering. The Sales Agreement will remain
in full force and effect until the Sales Agreement is terminated in accordance with the terms thereof.
This is a brief summary of the material provisions
of the Sales Agreement and does not purport to be a complete statement of its terms and conditions. A copy of the Sales Agreement is
filed as an exhibit to the registration statement of which this prospectus forms a part.
The Sales Agents and their respective
affiliates may in the future provide various investment banking and other financial services for us for which services they may in
the future receive customary fees. The principal business address of Chardan is One Pennsylvania Plaza, Suite 4800, New York, NY
10119. The principal business address of Craig-Hallum is 222 South Ninth Street, Suite 350, Minneapolis, MN 55402.
LEGAL MATTERS
The validity of the securities offered will be
passed upon for us by Blank Rome LLP, New York, New York. Lowenstein Sandler LLP, New York, New York is acting as counsel for the Sales
Agents in connection with this offering.
EXPERTS
The consolidated financial statements of iBio
Inc. and Subsidiaries for the two years ended June 30, 2023 have been audited by CohnReznick LLP, independent registered public accounting
firm, as set forth in their report thereon appearing in iBio Inc. and Subsidiaries Annual report on Form 10-K for the year ended June 30, 2023, and incorporated by reference herein. Such consolidated financial statements are incorporated by reference herein in reliance
upon such report, which includes an explanatory paragraph on our ability to continue as a going concern, given on the authority of such
firm as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
This prospectus is part of a registration statement
we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits
to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we
refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any
agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these
securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as
of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any
sale of the securities offered by this prospectus.
We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at www.sec.gov.
Additional information about iBio, Inc. is contained at our website, www.ibioinc.com. Information on our website is not incorporated
by reference into this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports
are filed with the SEC.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to “incorporate by reference”
information into this prospectus, which means that we can disclose important information to you by referring you to another document filed
separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-35023. The documents
incorporated by reference into this prospectus contain important information that you should read about us.
The following documents are incorporated by reference
into this prospectus:
|
· |
Our Current Reports on
Form 8-K filed with the SEC on August
4, 2023, August
7, 2023, September
21, 2023, October
10, 2023, November
28, 2023, December
6, 2023, December
8, 2023, December
26, 2023, January
19, 2024, February
21, 2024, February
26, 2024, April
1, 2024, May
20, 2024, June
5, 2024, July 3,
2024, July 9, 2024
and July 26, 2024; and |
|
· |
The description of our Common Stock set forth in: (i) our registration statement on Form 8-A filed with the SEC on March 19, 2014, including any amendments thereto or reports filed for the purposes of updating this description, and (ii) Exhibit 4.10 to our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 filed with the SEC on September 28, 2021. |
We also incorporate by reference into this prospectus
all documents (other than portions of those documents not deemed filed) that are filed by us with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act (Commission File Number 001-35023) after (i) on
or after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness
of such registration statement, and (ii) on or after the date of this prospectus but prior to the termination of the offering (i.e., until
the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this
prospectus forms a part has been withdrawn). These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. Information in such future filings updates and supplements
the information provided in this prospectus.
We will provide to each person, including any
beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents
that are incorporated by reference into this prospectus but not delivered with this prospectus, including exhibits that are specifically
incorporated by reference into such documents. You can request a copy of these filings, at no cost, by writing or telephoning us at the
following address or telephone number:
iBio, Inc.
11750 Sorrento Valley Road, Suite 200
San Diego, CA 92121
(979) 446-0027
Any statement contained in this prospectus or
in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
of this prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed document which also
is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
You may also access these documents, free of charge,
on the SEC’s website at www.sec.gov or on our website at www.ibioinc.com. The information contained in, or that can
be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus or any accompanying prospectus
supplement.
In accordance with Rule 412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement.
You should rely only on information contained
in, or incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with
information different from that contained in this prospectus or incorporated by reference into this prospectus. We are not making offers
to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such
offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation.
PROSPECTUS
$150,000,000
![](https://www.sec.gov/Archives/edgar/data/1420720/000110465924086336/tm2418807d1_s3img001.jpg)
IBIO, INC.
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
We may, from time to time, offer and sell up to
$150,000,000 of any combination of our common stock, par value $0.001 (the “Common Stock”), preferred stock, par value $0.001
(the “Preferred Stock”), debt securities, warrants or units described in this prospectus, either individually or in combination
with other securities, at prices and on terms described in one or more supplements to this prospectus. We may also offer Common Stock
or Preferred Stock upon conversion of debt securities, Common Stock upon conversion of Preferred Stock, or Common Stock, Preferred Stock,
or debt securities upon the exercise of warrants.
This prospectus provides you with a general description
of the securities that we may offer. Each time we offer and sell securities, we will provide a supplement to this prospectus that contains
specific information about the offering and the amounts, prices and terms of the securities. We may also authorize one or more free writing
prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus
may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus
supplement and any related free writing prospectus, as well as the documents incorporated by reference, before buying any of the securities
being offered.
Securities may be sold by us to or through underwriters
or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of sale,
you should refer to the section entitled “Plan of Distribution” in this prospectus and in the applicable prospectus supplement.
If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price,
fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth,
in the applicable prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such
sale will also be set forth in a prospectus supplement. No securities may be sold without delivery of this prospectus and the applicable
prospectus supplement describing the method and terms of the offering of such securities.
Our Common Stock is listed on the NYSE American
LLC under the symbol “IBIO.” On July 19, 2024, the last reported sale price of our Common Stock on the NYSE American LLC
was $2.15 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any,
on any securities market or other exchange of the specific security covered by such prospectus supplement.
As of the date of this prospectus, the aggregate
market value of our outstanding Common Stock held by non-affiliates is approximately $22,134,382, which is calculated based on 8,612,600
shares of our outstanding Common Stock held by non-affiliates and a price of $2.57 per share, the closing price of our Common Stock on
June 13, 2024, which is the highest closing sale price of our Common Stock on the NYSE American LLC within the prior 60 days of this prospectus.
During the prior twelve calendar month period that ends on and includes the date hereof, we have not offered or sold any shares of our
Common Stock pursuant to General Instruction I.B.6 to Form S-3.
Investing in our securities involves a
high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” beginning
on page 8 of this prospectus and contained in the applicable prospectus supplement and in any free writing prospectuses we have
authorized for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by
reference into this prospectus.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
The date of this prospectus is August 6, 2024.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement
on Form S-3 that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration
process. Under this shelf registration statement, we may sell from time to time in one or more offerings up to a total dollar amount of
$150,000,000 of shares of Common Stock, Preferred Stock, various series of debt securities and/or warrants to purchase any of such securities,
either individually or as units in combination with other securities as described in this prospectus. Each time we sell any type or series
of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms
of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information
relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to
you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference
into this prospectus. To the extent that any statement that we make in a prospectus supplement is inconsistent with statements made in
this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in a prospectus supplement.
You should carefully read both this prospectus and the applicable prospectus supplement and any related free writing prospectus, together
with the additional information described under “Where You Can Find More Information,” before buying any of the securities
being offered.
THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE
A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT
Neither we, nor any agent, underwriter or dealer
has authorized any person to give any information or to make any representation other than those contained or incorporated by reference
in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which
we have referred you. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus, any
applicable supplement to this prospectus or any related free writing prospectus does not constitute an offer to sell or the solicitation
of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus, any applicable
supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy
securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.
You should not assume that the information contained
in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to
the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent
to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related
free writing prospectus is delivered, or securities are sold, on a later date.
This prospectus contains summaries of certain
provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information.
All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have
been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a
part, and you may obtain copies of those documents as described below under the section entitled “Where You Can Find More Information.”
Except as otherwise indicated herein or as the
context otherwise requires, references in this prospectus to “iBio,” “the Company,” “we,” “us,”
“our” and similar references refer to iBio, Inc., an entity incorporated under the laws of the State of Delaware, and
where appropriate our consolidated subsidiaries.
This prospectus and the information incorporated
herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and
trade names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing
prospectus are the property of their respective owners.
PROSPECTUS SUMMARY
The following summary highlights information
contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the information that may be important
to purchasers of our securities. Prospective purchasers of our securities should carefully read the entire prospectus, the applicable
prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the
heading “Risk Factors” contained in this prospectus, the applicable prospectus supplement and any related free writing prospectus,
and under similar headings in the other documents that are incorporated by reference into this prospectus. Prospective purchasers of our
securities should also carefully read the information incorporated by reference into this prospectus, including our financial statements,
and the exhibits to the registration statement of which this prospectus is a part.
Overview
iBio, Inc. (“iBio,”
“we,” “us,” or “our”) is a pre-clinical pioneering biotechnology company at the intersection of AI
and biologics, committed to reshaping the landscape of discovery. Our core mission is to harness the potential of AI and machine learning
to unveil elusive biologics that stand out and have evaded other scientists. Through our innovative platform, we champion a culture of
innovation by identifying novel targets, forging strategic collaborations to enhance efficiency, diversify pipelines, and with the goal
of accelerating preclinical processes. During the past few years, we have focused on the development
of vaccines and therapeutics for commercialization. Our current focus is immune-oncology therapeutics. Our current vaccines and
therapeutics being developed are all in preclinical development and we have not completed any clinical trials for any vaccine or therapeutic
protein product candidate produced using iBio technology and there is a risk that we will be unsuccessful in developing or commercializing
any product candidates.
Our EngageTx™
technology enables us to target bi-specific molecules. Our pre-clinical data demonstrates our ability to generate multiple hits creating
sequence diversity and promoting Human-Cyno cross reactivity while mitigating cytokine release, our goal is to enhance agility and bolster
preclinical safety assessments.
Our strategic approach
to fulfilling our mission is outlined as follows:
| ● | Elevate Epitope Discovery:
Our patented AI-engine is being used to uncover "hard to develop" molecules. Our
epitope engine allows us to target select regions of a protein, with the goal of removing
the lengthy trial and error out of mAb discovery. This capability is being used to generate
preclinical data aimed at improving the probability of successfully determining which candidates
to further develop, which would reduce costs and time commonly caused by having an iterative
process. Our epitope engine is engineered to match its target, refined for stability and
optimized for water solubility, allowing us to identify new drug candidates that have failed
or have been abandoned due to their complexity. |
| ● | Capital Efficient Business Approach: Our strategic business approach is structured around the following
pillars of value creation: |
| o | Strategic Partnerships: We are leveraging our platform and pipeline by forming strategic partnerships.
Our aim is to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration
of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, a rich array of fast follower
molecules within our pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects.
By tapping into our platform, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to
biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency. |
| o | Tech Licensing in Diverse Therapeutic Areas: In pursuit of adding value, we are exploring partnerships
in diverse therapeutic domains such as CNS or vaccines. Our intention is to license the AI tech stack, extending its benefits to our partners
and amplifying its biological impact and insights. This strategic approach enables us to capitalize on the value of our meticulously curated
data while empowering collaborations and innovations. |
| o | Developing and Advancing Our In-house Programs Cost Effectively: Clinical advancement is crucial
for drug discovery. We are actively looking for opportunities to progress our internal pre-clinical programs, with a focal point on oncology,
obesity, and cardiometabolic diseases, steadily reinforcing our pre-clinical pipeline. |
| ● | Unwavering Investment in Advancing the Platform: We maintain an unwavering commitment to invest
in our platform, continually unlocking the potential of biology through AI and machine learning – the pinnacle of being on the forefront
of machine learning advancing algorithms and models in order to improve its predictive power and reduce the time it takes to find a viable
molecule. |
In essence, we are sculpting
a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating
innovation, and propelling the advancement of science.
Recent Developments
April Private Placement
On March 26, 2024, we entered into a securities
purchase agreement (the “Purchase Agreement”) with several institutional investors and an accredited investor (the “Purchasers”)
for the issuance and sale in a Private Placement of the following securities for gross proceeds of approximately $15.1 million: (i) 2,701,315
shares of Common Stock (the “Private Placement Shares”), (ii) Pre-Funded Warrants to purchase up to 2,585,963 shares of Common
Stock at an exercise price of $0.001 per share, and (iii) Series E Common Warrants to purchase up to 5,287,278 shares of Common Stock
at an exercise price of $2.64 per share. The Series E Common Warrants are exercisable at any time after the six-month anniversary of their
issuance (the “Initial Exercise Date”) at an exercise price of $2.64 per share and have a term of exercise equal to five years
from the date of issuance. On April 1, 2024, we closed the Private Placement. The combined purchase price for one share of Common Stock
and the accompanying Series E Common Warrant was $2.85 and the purchase price for one Pre-Funded Warrant and the accompanying Series E
Common Warrant was $2.849. The Company received net proceeds of approximately $14.1 million
from the Private Placement, after deducting estimated offering expenses payable by the Company, including placement agent fees and expenses.
A holder of the Pre-Funded Warrants and the Series
E Common Warrants may not exercise any portion of such holder’s Pre-Funded Warrants or the Series E Common Warrants to the extent
that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of our
outstanding shares of Common Stock immediately after exercise, except that upon at least 61 days’ prior notice from the holder to
us, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of Common Stock outstanding immediately
after giving effect to the exercise.
The Pre-Funded Warrants
are exercisable at any time after their original issuance, subject to the Beneficial Ownership Limitation (as defined below), and will
not expire until exercised in full. The exercise price and number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants
and Series E Common Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar
events affecting our Common Stock and the exercise price. If at the time of exercise on a date that is after the Initial Exercise Date,
there is no effective registration statement or the prospectus contained therein is not available for the issuance of shares of Common
Stock to the holder of the Series E Common Warrants, the Series E Common Warrant may also be exercised, in whole or in part, at such time
by means of a “cashless exercise.” If at the time of exercise on a date that is after the 60th day anniversary
of the Initial Exercise Date, there is no effective registration statement or the prospectus contained therein is not available for the
issuance of shares of Common Stock to the holder of the Pre-Funded Warrants, the Pre-Funded Warrants may also be exercised, in whole or
in part, at such time by means of a “cashless exercise.”
Pursuant to the Purchase
Agreement, we agreed to prepare and file a registration statement with the SEC registering the resale of the shares of Common Stock issued
to the Purchasers in the Private Placement and the shares underlying the Pre-Funded Warrants and the Series E Common Warrants (collectively,
the “Shares”) no later than 60 days after the date of the Purchase Agreement (the “Filing Date”), to use commercially
reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event not more
than 75 days following the date of the Purchase Agreement (or 90 days following the date of the Purchase Agreement in the event of a “full
review” by the SEC) (the “Effectiveness Date”), and to keep such registration statement effective at all times for a
one year period after the closing date provided that the Company will have the right to suspend the registration statement for a period
of fifteen (15) days during such one year period without being in breach. In the event that the resale registration statement is not (i)
filed by the Filing Date or (ii) declared effective by the SEC by the Effectiveness Date, then, in addition to any other rights the Purchasers
may have under the Purchase Agreement or under applicable law, on the Filing Date or the Effectiveness Date for a maximum of six months
(each such date being referred to herein as an “Event Date”) and on each monthly anniversary of such Event Date (if the resale
registration statement shall not have been filed or declared effective by the applicable Event Date) until the resale registration statement
is filed or declared effective, the Company shall pay to each Purchaser an amount in cash, as partial liquidated damages and not as a
penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such Purchaser pursuant to the Purchase
Agreement for each security not registered, which amount shall be capped at 6%. The registration statement was declared effective on April
24, 2024.
Pursuant to the terms of the Purchase Agreement,
we are prohibited from entering into any agreement to issue Common Stock or Common Stock Equivalents (as defined in the Purchase Agreement)
involving a Variable Rate Transaction (as defined in the Purchase Agreement), subject to certain exceptions, for a period commencing on
March 26, 2024 and expiring one year from such Effective Date (as defined in the Purchase Agreement); provided that sixty (60) days after
the Effective Date entering into an at-the-market facility shall not be deemed a Variable Rate Transaction.
Side Letter Agreement
In connection with the
Private Placement, we entered into a side letter agreement (the “Letter Agreement”) with one investor, Lynx1 Capital Management
LP (“Lynx1”). Subject to the terms of the Letter Agreement, Lynx1 will be entitled to nominate one individual to serve as
a director on our Board of Directors for one three-year term commencing with our 2024 Annual Meeting of Stockholders.
Tenth Amendment to Credit Agreement
On May 14, 2024, iBio
CDMO LLC (“iBio CDMO”), our wholly owned subsidiary, and Woodforest National Bank (“Woodforest”) entered into
the Tenth Amendment (the “Tenth Amendment”) to the Credit Agreement, which was entered into on November 1, 2021, as previously
amended as of October 11, 2022, February 9, 2023, February 20, 2023, March 24, 2023, May 10, 2023, September 18, 2023, October 4, 2023,
December 22, 2023 and March 28, 2024 (the “Credit Agreement”), which amendment among other things, amends the Credit Agreement
to: (i) set the maturity date of the term loan to the earlier of (a) May 31, 2024, or (b) the acceleration of maturity of the term loan
in accordance with the Credit Agreement. As of May 14, 2024, the current balance of the term loan, including principal, interest, deferred
interest and late fees, under the Credit Agreement, was $13,138,008.
Purchase and Sale Agreement
On May 17, 2024, iBio
CDMO entered into a purchase and sale agreement, dated as of May 17, 2024 (the “Purchase and Sale Agreement”) with The Board
of Regents of the Texas A&M University System (“The Board of Regents”) pursuant to which iBio CDMO agreed to terminate
the Ground Lease Agreement with The Board of Regents, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground
Lease Agreement, dated as of December 22, 2015 (collectively, the “Ground Lease”), related to 21.401 acres in Brazos County,
Texas (the “Land”) and to sell to The Board of Regents: (i) the buildings, parking areas, improvements, and fixtures situated
on the Land (the “Improvements”); (iii) all iBio CDMO’s right, title, and interest in and to furniture, personal property,
machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and
situated thereon (collectively, the “Personal Property”); (iii) all iBio CDMO’s rights under the contracts and agreements
relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the “Contracts”);
and (iv) all iBio CDMO’s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the
Personal Property (the “Intangibles”; and together with the Ground Lease, Improvements and Personal Property, collectively,
the “Property”). On May 31, 2024, pursuant to the Purchase and Sale Agreement, iBio CDMO terminated the Ground Lease and completed
the sale to The Board of Regents of the Property. Pursuant to the Purchase and Sale Agreement, iBio CDMO received $8,500,000 from The
Board of Regents upon the closing of the sale of Property, which was paid to Woodforest as described below.
On May 31, 2024, pursuant
to the terms of a Settlement Agreement and Mutual Release, dated May 17, 2024 by and among iBio CDMO, the Company and Woodforest (the
“Settlement Agreement”), iBio CDMO paid to Woodforest the proceeds of the sale of the Property under the Purchase and Sale
Agreement and thereafter we issued to Woodforest, in full satisfaction of the obligations of iBio CDMO and us pursuant to the Credit Agreement,
a pre-funded warrant (“Pre-Funded Warrant”) that expires upon full exercise thereof and is exercisable at a nominal exercise
price equal to $0.0001 per share for 1,560,570 shares of our Common Stock which equals the remaining balance due under the Credit Agreement
of $4,499,124.88 (the “Indebtedness Deficiency Amount”) divided by $2.883 (the greater of the book value or the market value
of our Common Stock at the time the Settlement Agreement is executed), which Pre-Funded Warrant Woodforest agreed to purchase in satisfaction
of the Indebtedness Deficiency Amount upon the closing of the sale of the Property under the Purchase and Sale Agreement. Pursuant to
the Settlement Agreement, Woodforest released us and iBio CDMO from any and all claims, debts, liabilities or causes of action it may
have against us and/or iBio CDMO prior to such date, and we and iBio CDMO agreed to release Woodforest and its related parties from any
and all claims, debts, liabilities or causes of action we and/or iBio CDMO may have against them prior to such date.
Corporate Information
We were incorporated under the laws of the State
of Delaware on April 17, 2008, under the name iBioPharma, Inc. We engaged in a merger with InB:Biotechnologies, Inc., a
New Jersey corporation on July 25, 2008, and changed our name to iBio, Inc. on August 10, 2009.
Our principal executive offices are located at
11750 Sorrento Valley Road, Suite 200, San Diego, CA 92121 and our telephone number is (979) 446-0027. Our website address is www.ibioinc.com.
Information contained on our website is intended for informational purposes only and is not incorporated by reference into this prospectus,
and it should not be considered to be part of this prospectus or the registration statement of which this prospectus forms a part. The
SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers like us
that file documents electronically with the SEC. The address of the SEC website is www.sec.gov.
Smaller Reporting Company
We are a “smaller reporting company”
as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As a result, we may take advantage of
certain reduced disclosure obligations available to smaller reporting companies, including the exemption from compliance with the auditor
attestation requirements pursuant to the Sarbanes-Oxley Act of 2022, reduced disclosure about our executive compensation arrangements
and the requirements to provide only two years of audited financial statements in our annual reports and registration statements. We will
continue to be a “smaller reporting company” as long as (1) we have a public float (i.e., the market value of our Common
Stock held by non-affiliates) less than $250 million calculated as of the last business day of our most recently completed second fiscal
quarter, or (2) our annual revenues are less than $100 million for our previous fiscal year and we have either no public float or
a public float of less than $700 million as of the end of that fiscal year’s second fiscal quarter. Decreased disclosures in our
SEC filings due to our status as a “smaller reporting company” may make it harder for investors to analyze our results of
operations and financial prospects.
Risks Associated with our Business
Our business is subject to numerous risks, as
described under the heading “Risk Factors” contained in the applicable prospectus supplement and in any free writing prospectuses
we have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated by
reference into this prospectus.
The Securities We May Offer
We may offer shares of our Common Stock, Preferred
Stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or as units in combination
with other securities, with a total value of up to $150,000,000 from time to time under this prospectus at prices and on terms to be determined
at the time of any offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer
a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts,
prices and other important terms of the securities, including, to the extent applicable:
| ● | designation or classification; |
| ● | aggregate principal amount or aggregate offering price; |
| ● | original issue discount; |
| ● | rates and times of payment of interest or dividends; |
| ● | redemption, conversion, exercise, exchange or sinking fund terms; |
| ● | conversion or exchange prices or rates and, if applicable, any
provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable
upon conversion or exchange; and |
| ● | a discussion of material United States federal income tax considerations,
if any. |
The prospectus supplement and any related free
writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus
or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security
that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus
is a part.
We may sell the securities directly to investors
or to or through agents, underwriters or dealers. We, and our agents, underwriters or dealers reserve the right to accept or reject all
or part of any proposed purchase of securities. If we do offer securities to or through agents, underwriters or dealers, we will include
in the applicable prospectus supplement:
● the
names of those agents, underwriters, or dealers;
● applicable
fees, discounts and commissions to be paid to them;
● details
regarding over-allotment options, if any; and
● the
net proceeds to us.
The following is a summary of the securities we
may offer with this prospectus.
Common Stock
We may issue shares of our Common Stock from time
to time. Each holder of our Common Stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders,
including the election of directors. Subject to preferences that may be applicable to any outstanding Preferred Stock, the holders of
Common Stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the board of directors out
of funds legally available therefor. In the event of our liquidation, dissolution or winding up, the holders of Common Stock are entitled
to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of Preferred Stock, if any,
then outstanding. The holders of our Common Stock have no preemptive, subscription, cumulative voting or conversion rights and there are
no redemption or sinking fund provisions applicable to our Common Stock. The rights, preferences and privileges of the holders of Common
Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of Preferred Stock that we may
designate in the future.
Preferred Stock
Our board of directors is authorized to issue
up to 1,000,000 shares of Preferred Stock in one or more series without stockholder approval. Our board of directors may determine the
rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and
liquidation preferences, of each series of Preferred Stock. Convertible Preferred Stock will be convertible into our Common Stock or exchangeable
for other securities. Conversion may be mandatory or at the holder’s option and would be at prescribed conversion rates. If we sell
any series of Preferred Stock under this prospectus, we will fix the designations, voting powers, preferences and rights of such series
of Preferred Stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to
that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference
from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of Preferred
Stock that we are offering before the issuance of the related series of Preferred Stock.
We urge you to read the applicable prospectus
supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of Preferred Stock being
offered, as well as the complete certificate of designation that contains the terms of the applicable series of Preferred Stock.
Debt Securities
We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities
will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in
right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible
debt securities will be convertible into or exchangeable for our Common Stock or other securities. Conversion may be mandatory or at your
option and would be at prescribed conversion rates.
Any debt securities issued under this prospectus
will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other
eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however,
to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to
the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form
of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures
and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement
of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.
Warrants
We may issue warrants for the purchase of Common
Stock, Preferred Stock and/or debt securities in one or more series. We may issue warrants independently or as units in combination with
Common Stock, Preferred Stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus,
we have summarized certain general features of the warrants.
We urge you, however, to read the applicable prospectus
supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of warrants being offered,
as well as any warrant agreements and warrant certificates that contain the terms of the warrants. We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant
and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are
offering, and any supplemental agreements, before the issuance of such warrants.
Any warrants issued under this prospectus may
be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant agreement that we enter into with a warrant
agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular
series of warrants being offered.
Units
We may issue units consisting of any combination
of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit certificates
that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or
trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating
to a particular series of units.
In this prospectus, we have summarized certain
general features of the units under “Description of Units.” We urge you, however, to read the applicable prospectus supplement
(and any related free writing prospectus that we may authorize to be provided to you) related to the series of units being offered, as
well as the complete unit agreement that contains the terms of the units. We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the specific unit agreement that contains
the terms of the particular series of units we are offering, before the issuance of such units.
SELECTED
FINANCIAL DATA REFLECTING THE 2023 REVERSE STOCK SPLIT
On
November 29, 2023, we effected a 1-for-20 reverse stock split of our Common Stock (the “2023 Reverse Stock Split”).
The total number of outstanding shares of Common Stock was reduced from approximately 28,100,733
to approximately 1,405,036 shares. The par value per common share remained unchanged.
The audited consolidated financial statements of the Company included in the Annual Report on Form 10-K for the year ended
June 30, 2023, and the unaudited condensed consolidated financial statements included in our Quarterly Report on Form 10-Q for
the period ended March 31, 2024, which are incorporated by reference into this prospectus are presented without giving effect to
the 2023 Reverse Stock Split.
The
following selected financial data has been derived from our audited consolidated financial statements included in our Annual Report on
Form 10-K filed with the SEC on September 27, 2023, and our unaudited condensed consolidated financial statements included
in our Quarterly Report on Form 10-Q filed with the SEC on May 13, 2024, as adjusted to reflect the 2023 Reverse Stock Split
for all periods presented. Our historical results are not indicative of the results that may be expected in the future and results of
interim periods are not indicative of the results for the entire year.
The
following table presents selected share information reflecting the 2023 Reverse Stock Split for the years ended June 30, 2023 and 2022:
| |
Year Ended
June 30, | |
| |
2023 | | |
2022 | |
Weighted-average common shares outstanding
- pre-split | |
| 12,244,969 | | |
| 8,721,324 | |
Weighted-average common shares outstanding - post-split | |
| 612,248 | | |
| 436,066 | |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - pre-split | |
$ | (2.39 | ) | |
$ | (3.39 | ) |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - post-split | |
$ | (47.87 | ) | |
$ | (67.88 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - pre-split | |
$ | (2.92 | ) | |
$ | (2.39 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - post-split | |
$ | (58.31 | ) | |
$ | (47.68 | ) |
Basic and diluted net loss per share attributable to common
stockholders - pre-split | |
$ | (5.31 | ) | |
$ | (5.78 | ) |
Basic and diluted net loss per share attributable to common
stockholders - post-split | |
$ | (106.18 | ) | |
$ | (115.56 | ) |
The
following table presents selected share information reflecting the 2023 Reverse Stock Split for the three months ended March 31, 2024
and 2023:
| |
2024 | | |
2023 | |
Weighted-average common shares outstanding
- pre-split | |
| | | |
| 13,184,219 | |
Weighted-average common shares outstanding - post-split | |
| 3,713,103 | | |
| 659,210 | |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - pre-split | |
| | | |
$ | (0.47 | ) |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - post-split | |
$ | (0.71 | ) | |
$ | (9.53 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - pre-split | |
| | | |
$ | (0.08 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - post-split | |
$ | (0.14 | ) | |
$ | (1.54 | ) |
Basic and diluted net loss per share attributable to common
stockholders - pre-split | |
| | | |
$ | (0.55 | ) |
Basic and diluted net loss per share attributable to common
stockholders - post-split | |
$ | (0.85 | ) | |
$ | (11.07 | ) |
The
following table presents selected share information reflecting the 2023 Reverse Stock Split for the nine months ended March 31, 2024
and 2023:
| |
2024 | | |
2023 | |
Weighted-average common shares outstanding
- pre-split | |
| | | |
| 10,592,240 | |
Weighted-average common shares outstanding - post-split | |
| 2,247,250 | | |
| 529,611 | |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - pre-split | |
| | | |
$ | (2.30 | ) |
Basic and diluted net loss per share from continuing operations
attributable to common stockholders - post-split | |
$ | (5.43 | ) | |
$ | (46.00 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - pre-split | |
| | | |
$ | (3.27 | ) |
Basic and diluted net loss per share from discontinued
operations attributable to common stockholders - post-split | |
$ | (2.19 | ) | |
$ | (65.28 | ) |
Basic and diluted net loss per share attributable to common
stockholders - pre-split | |
| | | |
$ | (5.57 | ) |
Basic and diluted net loss per share attributable to common
stockholders - post-split | |
$ | (7.62 | ) | |
$ | (111.28 | ) |
| |
| | | |
| | |
RISK FACTORS
Investing in our securities involves a high degree
of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties described under
the heading “Risk Factors” contained in the applicable prospectus supplement and any related free writing prospectus, and
discussed under the section entitled “Risk Factors” contained in our most recent Annual Report on Form 10-K, as may be
updated by subsequent annual, quarterly and other reports that are incorporated by reference into this prospectus in their entirety. The
risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown
or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results.
Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate
results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of operations or
cash flow could be seriously harmed. This could cause the trading price of our Common Stock to decline, resulting in a loss of all or
part of your investment. Please also read carefully the section below entitled “Forward-Looking Statements.”
FORWARD-LOOKING STATEMENTS
This prospectus, including the documents that
we incorporate by reference herein, contains, and any applicable prospectus supplement or free writing prospectus including the documents
we incorporate by reference therein may contain, forward-looking statements within the meaning of Section 27A of the Securities Act
of 1933, as amended (the “Securities Act”) and Section 21E of the Exchange Act, including statements regarding our future
financial condition, business strategy and plans and objectives of management for future operations. Forward-looking statements include
all statements that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as “believe,”
“will,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “might,” “approximately,” “expect,” “predict,”
“could,” “potentially” or the negative of these terms or other similar expressions. Forward-looking statements
include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations.
Discussions containing these forward-looking statements
may be found, among other places, in the sections entitled “Business,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” contained in the documents incorporated by reference herein,
including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K,
as well as any amendments thereto.
These statements relate to future events or our
future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results,
levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements.
We discuss in greater detail, and incorporate by reference into this prospectus in their entirety, many of these risks and uncertainties
under the heading “Risk Factors” contained in the applicable prospectus supplement, in any free writing prospectus we may
authorize for use in connection with a specific offering, and in the documents incorporated by reference herein. These statements reflect
our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. We undertake no obligation
to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement.
USE OF PROCEEDS
We will retain broad discretion over the use of
the net proceeds from the sale of the securities offered hereby. Except as described in any prospectus supplement or in any related free
writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds from the sale of the securities
offered by us hereunder primarily for working capital and general corporate purposes. We will set forth in the applicable prospectus supplement
or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus
supplement or free writing prospectus.
DESCRIPTION OF CAPITAL STOCK
The following description of our capital stock
and the provisions of our certificate of incorporation, as amended (the “Certificate of Incorporation”) and our second amended
and restated bylaws (the “Bylaws”) are summaries and are qualified by reference to the Certificate of Incorporation and the
Bylaws. We have filed copies of these documents with the SEC as exhibits to our registration statement of which this prospectus forms
a part. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation
Law, for additional information.
General
Our authorized capital stock consists of 275,000,000
shares of Common Stock, par value $0.001 per share, and 1,000,000 shares of Preferred Stock, par value $0.001 per share.
As of July 19, 2024, 8,623,685 shares
of our Common Stock are issued and outstanding, and no shares of our Preferred Stock are issued and outstanding.
Common Stock
Authorized Shares of Common Stock. We
currently have authorized 275,000,000 shares of Common Stock.
Voting. The holders of Common Stock
are entitled to one vote per share on all matters to be voted upon by the stockholders, except on matters relating solely to terms of
Preferred Stock.
Dividends. Subject to preferences
that may be applicable to any outstanding Preferred Stock, the holders of Common Stock are entitled to receive ratably such dividends,
if any, as may be declared from time to time by the board of directors out of funds legally available therefor.
Liquidation. In the event of our liquidation,
dissolution or winding up, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of liabilities,
subject to prior distribution rights of Preferred Stock, if any, then outstanding.
Other Rights and Preferences. The
holders of our Common Stock have no preemptive, subscription, cumulative voting or conversion rights and there are no redemption or sinking
fund provisions applicable to our Common Stock.
Preferred Stock
Our board of directors is authorized to issue
up to 1,000,000 shares of Preferred Stock in one or more series without stockholder approval. Our board of directors may determine the
rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and
liquidation preferences, of each series of Preferred Stock.
The issuance of Preferred Stock, while providing
desirable flexibility in connection with possible acquisitions and other corporate purposes, could make it more difficult for a third
party to acquire, or could discourage a third party from acquiring, a majority of our outstanding voting stock. The rights of holders
of our Common Stock described above, will be subject to, and may be adversely affected by, the rights of any Preferred Stock that we may
designate and issue in the future.
NYSE American Listing
Our Common Stock is listed on the NYSE American
under the symbol “IBIO.”
Transfer Agent and Registrar
The transfer agent and
registrar for our Common Stock is Continental Stock Transfer & Trust Company. Continental Stock Transfer & Trust Company
is located at 1 State Street, 30th Floor, New York, New York 10004. Their telephone number is (212) 509-4000.
Potential Anti-Takeover Effects
Certain provisions set forth in our Certificate
of Incorporation and our Bylaws and in Delaware law, which are summarized below, may be deemed to have an anti-takeover effect and may
delay, deter or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including attempts
that might result in a premium being paid over the market price for the shares held by stockholders.
Pursuant to our Certificate of Incorporation,
our board of directors may issue additional shares of Common Stock or Preferred Stock. Any additional issuance of Common Stock could have
the effect of impeding or discouraging the acquisition of control of us by means of a merger, tender offer, proxy contest or otherwise,
including a transaction in which our stockholders would receive a premium over the then-current market price for their shares, and thereby
protect the continuity of our management. Specifically, if in the due exercise of its fiduciary obligations, the board of directors were
to determine that a takeover proposal was not in our best interest, shares could be issued by our board of directors without stockholder
approval in one or more transactions that might prevent or render more difficult or costly the completion of the takeover by:
|
· |
diluting the voting or other rights of the proposed acquirer or insurgent stockholder group; |
|
· |
putting a substantial voting block in institutional or other hands that might undertake to support the incumbent board of directors; or |
|
· |
effecting an acquisition that might complicate or preclude the takeover. |
Our Bylaws provide that our board of directors
shall establish the number of directors. Cumulative voting in the election of directors is not permitted by our Certificate of Incorporation.
Not providing for cumulative voting may delay or prevent a tender offer or takeover attempt that a stockholder may determine to be in
his, her or its best interest, including attempts that might result in a premium over the market price for the shares held by the stockholders.
In addition to the foregoing, our Bylaws contain
the following provisions:
Staggered Board. Our
board of directors is divided into three classes of directors, Class I, II and III, with each class serving a term ending at
the third annual meeting following its election.
Nominations of Directors
and Proposals of Business. Our Bylaws generally regulate nominations for election of directors by stockholders and proposals of business
at annual meetings. In general, Sections 1.10 and 1.11 of our Bylaws requires stockholders intending to submit nominations or proposals
at an annual meeting of stockholders to provide the Company with advance notice thereof, including information regarding the stockholder
proposing the business as well as information regarding the nominee or the proposed business. Sections 1.10 and 1.11 of our Bylaws provides
a time period during which nominations or business must be provided to the Company that creates a predictable window for the submission
of such notices, eliminating the risk that the Company finds a meeting will be contested after printing its proxy materials for an uncontested
election and providing the Company with a reasonable opportunity to respond to nominations and proposals by stockholders.
Board Vacancies. Our
Bylaws generally provide that only the board of directors (and not the stockholders) may fill vacancies and newly created directorships.
Special Meeting of Stockholders.
Our Bylaws generally provide that special meetings of stockholders for any purpose or purposes for which meetings may be lawfully
called, may be called at any time by our board of directors, the Chairman of the Board, the Chief Executive Officer or by one or more
stockholders holding shares in the aggregate entitled to cast not less than fifty percent (50%) of the votes at that meeting. Business
transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice
of meeting.
While the foregoing provisions of our Certificate
of Incorporation, our Bylaws and Delaware law may have an anti-takeover effect, these provisions are intended to enhance the likelihood
of continuity and stability in the composition of the board of directors and in the policies formulated by the board of directors and
to discourage certain types of transactions that may involve an actual or threatened change of control. In that regard, these provisions
are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain
tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers
for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our Common Stock that could result from
actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management.
Delaware Takeover Statute
Pursuant to our Certificate of Incorporation,
we have expressly elected not to be subject to Section 203 of the Delaware General Corporation Law (the “DGCL”). Subject
to certain exceptions (including a corporation’s express election not to be governed by Section 203), Section 203 prevents
a publicly held Delaware corporation from engaging in a “business combination” with any “interested stockholder”
for three years following the date that the person became an interested stockholder, unless the interested stockholder attained such status
with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A “business combination”
includes, among other things, a merger or consolidation involving us and the “interested stockholder” and the sale of more
than 10% of our assets. In general, an “interested stockholder” is any entity or person beneficially owning 15% or more of
our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.
Stock Options
As of July 19, 2024, we had options outstanding
to purchase an aggregate of 910,044 shares of Common Stock that were issued under our equity compensation plans. As of July 19, 2024,
there were 251,600 shares of Common Stock reserved for future issuance under our equity incentive plan.
Warrants
As of July 19, 2024, there are 12,125,198
shares of Common Stock issuable upon the exercise of outstanding warrants.
DESCRIPTION OF DEBT SECURITIES
We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized
below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any
debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under
a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture,
we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.
We will issue the debt securities under the indenture
that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939,
as amended (the “Trust Indenture Act”). We have filed the form of indenture as an exhibit to the registration statement of
which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities
being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference
from reports that we file with the SEC.
The following summary of material provisions of
the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture
applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement and any related free writing
prospectus related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the
terms of the debt securities.
General
The indenture will not limit the amount of debt
securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be
in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially
all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to
give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.
We may issue the debt securities issued under
the indenture as “discount securities,” which means they may be sold at a discount below their stated principal amount. These
debt securities, as well as other debt securities that are not issued at a discount, may be issued with “original issue discount,”
or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material
U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable
prospectus supplement.
We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including:
|
● |
the title of the series of debt securities; |
|
● |
any limit upon the aggregate principal amount that may be issued; |
|
● |
the maturity date or dates; |
|
● |
the form of the debt securities of the series; |
|
● |
the applicability of any guarantees; |
|
● |
whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; |
|
● |
whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; |
|
|
|
|
● |
if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined; |
|
● |
the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; |
|
● |
our right, if any, to defer payment of interest and the maximum length of any such deferral period; |
|
● |
if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; |
|
● |
the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder’s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; |
|
● |
the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; |
|
● |
any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; |
|
● |
any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; |
|
● |
any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; |
|
● |
whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; |
|
● |
if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders’ option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; |
|
● |
if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; |
|
● |
additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; |
|
● |
additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; |
|
● |
additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; |
|
● |
additions to or changes in the provisions relating to satisfaction and discharge of the indenture; |
|
● |
additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; |
|
● |
the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; |
|
● |
whether interest will be payable in cash or additional debt securities at our or the holders’ option and the terms and conditions upon which the election may be made; |
|
● |
the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a “United States person” for federal tax purposes; |
|
● |
any restrictions on transfer, sale or assignment of the debt securities of the series; and |
|
● |
any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. |
Conversion or Exchange Rights
We will set forth in the applicable prospectus
supplement the terms on which a series of debt securities may be convertible into or exchangeable for our Common Stock or our other securities.
We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option
of the holder or at our option. We may include provisions pursuant to which the number of shares of our Common Stock or our other securities
that the holders of the series of debt securities receive would be subject to adjustment.
Consolidation, Merger or Sale
Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability
to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety.
However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture
or the debt securities, as appropriate.
Events of Default under the Indenture
Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect
to any series of debt securities that we may issue:
|
● |
if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; |
|
● |
if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; |
|
|
|
|
● |
if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and |
|
● |
if specified events of bankruptcy, insolvency or reorganization occur. |
If an event of default with respect to debt securities
of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders
of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the
trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and
payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of
and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action
on the part of the trustee or any holder.
The holders of a majority in principal amount
of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its
consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured
the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.
Subject to the terms of the indenture, if an event
of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or
powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such
holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities
of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee,
or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:
|
● |
the direction so given by the holder is not in conflict with any law or the applicable indenture; and |
|
|
|
|
● |
subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. |
A holder of the debt securities of any series
will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only
if:
|
● |
the holder has given written notice to the trustee of a continuing event of default with respect to that series; |
|
|
|
|
● |
the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, |
|
|
|
|
● |
such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and |
|
|
|
|
● |
the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. |
These limitations do not apply to a suit instituted
by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.
We will periodically file statements with the
trustee regarding our compliance with specified covenants in the indenture.
Modification of Indenture; Waiver
We and the trustee may change an indenture without
the consent of any holders with respect to specific matters:
|
● |
to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; |
|
|
|
|
● |
to comply with the provisions described above under “Description of Debt Securities—Consolidation, Merger or Sale;” |
|
|
|
|
● |
to provide for uncertificated debt securities in addition to or in place of certificated debt securities; |
|
|
|
|
● |
to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; |
|
|
|
|
● |
to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; |
|
● |
to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; |
|
|
|
|
● |
to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under “Description of Debt Securities—General” to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; |
|
● |
to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or |
|
● |
to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. |
In addition, under the indenture, the rights of
holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority
in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise
in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only
with the consent of each holder of any outstanding debt securities affected:
|
● |
extending the fixed maturity of any debt securities of any series; |
|
|
|
|
● |
reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or |
|
|
|
|
● |
reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. |
Discharge
Each indenture provides that we can elect to be
discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations
to:
|
● |
provide for payment; |
|
|
|
|
● |
register the transfer or exchange of debt securities of the series; |
|
|
|
|
● |
replace stolen, lost or mutilated debt securities of the series; |
|
● |
pay principal of and premium and interest on any debt securities of the series; |
|
|
|
|
● |
maintain paying agencies; |
|
|
|
|
● |
hold monies for payment in trust; |
|
|
|
|
● |
recover excess money held by the trustee; |
|
|
|
|
● |
compensate and indemnify the trustee; and |
|
|
|
|
● |
appoint any successor trustee. |
In order to exercise our rights to be discharged,
we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest
on, the debt securities of the series on the dates payments are due.
Form, Exchange and Transfer
We will issue the debt securities of each series
only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations
of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent
global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another
depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities
of a series are issued in global form and as book-entry, a description of terms relating such securities will be set forth in the applicable
prospectus supplement.
At the option of the holder, subject to the terms
of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of
the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination
and of like tenor and aggregate principal amount.
Subject to the terms of the indenture and the
limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present
the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed
if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated
by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose
no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.
We will name in the applicable prospectus supplement
the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities.
We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office
through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt
securities of each series.
If we elect to redeem the debt securities of any
series, we will not be required to:
|
● |
issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or |
|
|
|
|
● |
register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. |
Information Concerning the Trustee
The trustee, other than during the occurrence
and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the
applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would
exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any
of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity
against the costs, expenses and liabilities that it might incur.
Payment and Paying Agents
Unless we otherwise indicate in the applicable
prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose
name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for
the interest.
We will pay principal of and any premium and interest
on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate
in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to
certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of
the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus
supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying
agent in each place of payment for the debt securities of a particular series.
All money we pay to a paying agent or the trustee
for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after
such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may
look only to us for payment thereof.
Governing Law
The indenture and the debt securities will be
governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture
Act is applicable.
DESCRIPTION OF WARRANTS
The following description, together with the additional
information we may include in any applicable prospectus supplement and in any related free writing prospectus, summarizes the material
terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase Common Stock,
Preferred Stock or debt securities and may be issued in one or more series. Warrants may be offered independently or in combination with
Common Stock, Preferred Stock or debt securities offered by any prospectus supplement. While the terms we have summarized below will apply
generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in
more detail in the applicable prospectus supplement. The following description of warrants will apply to the warrants offered by this
prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular
series of warrants may specify different or additional terms.
We have filed or will file forms of the warrant
agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration
statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part,
or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant
certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements,
before the issuance of such warrants. The following summaries of material terms and provisions of the warrants are subject to, and qualified
in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as
applicable, and any supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We
urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this prospectus,
as well as any related free writing prospectus, and the complete form of warrant and/or the warrant agreement and warrant certificate,
as applicable, and any supplemental agreements, that contain the terms of the warrants.
General
We will describe in the applicable prospectus
supplement the terms of the series of warrants being offered, including, to the extent applicable:
|
● |
the offering price and aggregate number of warrants offered; |
|
|
|
|
● |
the currency for which the warrants may be purchased; |
|
|
|
|
● |
the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; |
|
|
|
|
● |
the date on and after which the warrants and the related securities will be separately transferable; |
|
|
|
|
● |
in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; |
|
|
|
|
● |
in the case of warrants to purchase Common Stock or Preferred Stock, the number of shares of Common Stock or Preferred Stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; |
|
|
|
|
● |
the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; |
|
|
|
|
● |
the terms of any rights to redeem or call the warrants; |
|
|
|
|
● |
any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; |
|
|
|
|
● |
the dates on which the right to exercise the warrants will commence and expire; |
|
|
|
|
● |
the manner in which the warrant agreements and warrants may be modified; |
|
|
|
|
● |
a discussion of material United States federal income tax consequences of holding or exercising the warrants; |
|
● |
the terms of the securities issuable upon exercise of the warrants; and |
|
|
|
|
● |
any other specific terms, preferences, rights or limitations of or restrictions on the warrants. |
Before exercising their warrants, holders of warrants
will not have any of the rights of holders of the securities purchasable upon such exercise, including:
|
● |
in the case of warrants to purchase Common Stock or Preferred Stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any; or |
|
|
|
|
● |
in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture. |
Exercise of Warrants
Each warrant will entitle the holder to purchase
the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus
supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at
any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of
business on the expiration date, unexercised warrants will become void.
Unless we otherwise specify in the applicable
prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant or warrant certificate representing
the warrants to be exercised together with specified information, and paying the required amount to the warrant agent, if applicable,
in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of any warrant
certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to
any warrant agent in connection with the exercise of the warrant.
Upon receipt of payment and the warrant or warrant
certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent, if any, or any other
office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable
upon such exercise. If fewer than all of the warrants (or the warrants represented by such warrant certificate) are exercised, a new warrant
or a new warrant certificate, as applicable, will be issued for the remaining warrants.
Governing Law
Unless we provide otherwise in the applicable
prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants
or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York.
Enforceability of Rights by Holders of Warrants
Each warrant agent, if any, will act solely as
our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder
of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have
no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility
to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the
related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities
purchasable upon exercise of, its warrants.
DESCRIPTION OF UNITS
The following description, together with the additional
information we may include in any applicable prospectus supplement and related free writing prospectus, summarizes the material terms
and provisions of the units that we may offer under this prospectus. We may issue units consisting of any combination of the other types
of securities offered under this prospectus in one or more series. We will issue each unit so that the holder of the unit is also the
holder of each security included in the unit. As a result, the holder of a unit will have the rights and obligations of a holder of each
included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held
or transferred separately, at any time or at any time before a specified date. We may evidence each series of units by unit certificates
that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or
trust company that we select. We will indicate the name and address of any unit agent in the applicable prospectus supplement relating
to a particular series of units. The summary below and that contained in any prospectus supplement is qualified in its entirety by reference
to all of the provisions of the unit agreement and/or unit certificate, and depositary arrangements, if applicable. We urge you to read
the applicable prospectus supplements and any related free writing prospectuses related to the units that we may offer under this prospectus,
as well as the complete unit agreement and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of
the units.
We will file as exhibits to the registration statement
of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit agreement
and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of the particular series of units we are offering,
and any supplemental agreements, before the issuance of such units.
We will describe in the applicable prospectus
supplement the terms of the series of units being offered, including:
|
● |
the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; |
|
|
|
|
● |
any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities composing the units; |
|
|
|
|
● |
whether the units will be issued in fully registered or global form; and |
|
|
|
|
● |
any other terms of the units. |
LEGAL OWNERSHIP OF SECURITIES
We can issue securities in registered form or
in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have
securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this
purpose as the “holders” of those securities. These persons are the legal holders of the securities. We refer to those persons
who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as “indirect
holders” of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in
book-entry form or in street name will be indirect holders.
Book-Entry Holders
We may issue securities in book-entry form only,
as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities
registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate
in the depositary’s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial
interests in the securities on behalf of themselves or their customers.
Only the person in whose name a security is registered
is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants.
Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments
on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the
payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have
made with one another or with their customers; they are not obligated to do so under the terms of the securities.
As a result, investors in a global security will
not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial
institution that participates in the depositary’s book-entry system or holds an interest through a participant. As long as the securities
are issued in global form, investors will be indirect holders, and not legal holders, of the securities.
Street Name Holders
We may terminate a global security or issue securities
that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in “street
name.” Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution
that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains
at that institution.
For securities held in street name, we or any
applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the
securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those
securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only
because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities
in street name will be indirect holders, not holders, of those securities.
Legal Holders
Our obligations, as well as the obligations of
any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations
to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case
whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global
form.
For example, once we make a payment or give a
notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with
its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain
the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with
a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and
not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.
Special Considerations for Indirect Holders
If you hold securities through a bank, broker
or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in
street name, you should check with your own institution to find out:
|
● |
how it handles securities payments and notices; |
|
|
|
|
● |
whether it imposes fees or charges; |
|
● |
how it would handle a request for the holders’ consent, if ever required; |
|
|
|
|
● |
whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; |
|
|
|
|
● |
how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and |
|
|
|
|
● |
if the securities are in book-entry form, how the depositary’s rules and procedures will affect these matters. |
Global Securities
A global security is a security that represents
one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities
will have the same terms.
Each security issued in book-entry form will be
represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that
we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable
prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued
in book-entry form.
A global security may not be transferred to or
registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations
arise. We describe those situations below under “—Special Situations When a Global Security Will Be Terminated.” As
a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented
by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must
be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with
another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the
security, but only an indirect holder of a beneficial interest in the global security.
If the prospectus supplement for a particular
security indicates that the security will be issued in global form only, then the security will be represented by a global security at
all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry
clearing system or decide that the securities may no longer be held through any book-entry clearing system.
Special Considerations for Global Securities
As an indirect holder, an investor’s rights
relating to a global security will be governed by the account rules of the investor’s financial institution and of the depositary,
as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead
deal only with the depositary that holds the global security.
If securities are issued only as global securities,
an investor should be aware of the following:
|
● |
an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below; |
|
|
|
|
● |
an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above; |
|
|
|
|
● |
an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form; |
|
|
|
|
● |
an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; |
|
|
|
|
● |
the depositary’s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor’s interest in the global security; |
|
|
|
|
● |
we and any applicable trustee have no responsibility for any aspect of the depositary’s actions or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; |
|
● |
the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and |
|
|
|
|
● |
financial institutions that participate in the depositary’s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. |
There may be more than one financial intermediary
in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.
Special Situations When a Global Security Will
Be Terminated
In a few special situations described below, a
global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that
exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their
own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct
holders. We have described the rights of holders and street name investors above.
Unless we provide otherwise in the applicable
prospectus supplement, a global security will terminate when the following special situations occur:
|
● |
if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days; |
|
|
|
|
● |
if we notify any applicable trustee that we wish to terminate that global security; or |
|
|
|
|
● |
if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. |
The applicable prospectus supplement may also
list additional situations for terminating a global security that would apply only to the particular series of securities covered by the
applicable prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible
for deciding the names of the institutions that will be the initial direct holders.
PLAN OF DISTRIBUTION
We may sell the securities from time to time pursuant
to underwritten public offerings, direct sales to the public, “at the market” offerings, negotiated transactions, block trades
or a combination of these methods. We may sell the securities to or through one or more underwriters or dealers (acting as principal or
agent), through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:
|
● |
at a fixed price or prices, which may be changed; |
|
|
|
|
● |
at market prices prevailing at the time of sale; |
|
|
|
|
● |
at prices related to such prevailing market prices; or |
|
|
|
|
● |
at negotiated prices. |
A prospectus supplement or supplements (and any
related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities,
including, to the extent applicable:
|
● |
the name or names of the underwriters, dealers, agents or other purchasers, if any; |
|
|
|
|
● |
the purchase price of the securities or other consideration therefor, and the proceeds we will receive from the sale; |
|
|
|
|
● |
any option to purchase additional shares or other options under which underwriters, dealers, agents or other purchasers may purchase additional securities from us; |
|
|
|
|
● |
any agency fees or underwriting discounts to be allowed or paid to the agent or underwriters and other items constituting agents’ or underwriters’ compensation; |
|
|
|
|
● |
any public offering price; |
|
|
|
|
● |
any discounts or concessions allowed or reallowed or paid to dealers; and |
|
|
|
|
● |
any securities exchange or market on which the securities may be listed. |
Only underwriters named in the prospectus supplement
will be underwriters of the securities offered by the prospectus supplement. Dealers and agents participating in the distribution of the
securities may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting
discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities
Act.
If underwriters are used in the sale, they will
acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public
offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will
be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting
syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters
will be obligated to purchase all of the securities offered by the prospectus supplement other than securities covered by any option to
purchase additional shares or other option. If a dealer is used in the sale of securities, we, or an underwriter, will sell the securities
to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer
at the time of resale. To the extent required, we will set forth in the prospectus supplement the name of the dealer and the terms of
the transaction. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time
to time. We may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus supplement,
naming the underwriter, dealer or agent, the nature of any such relationship.
We may sell securities directly or through agents
we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions
we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a best-efforts
basis for the period of its appointment.
We may authorize agents or underwriters to solicit
offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe
the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.
We may provide agents, dealers and underwriters
with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments
that the agents, dealers or underwriters may make with respect to these liabilities. Agents, dealers and underwriters or their affiliates
may engage in transactions with, or perform services for, us in the ordinary course of business.
All securities we may offer, other than Common
Stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but
will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of
the trading markets for any securities.
Any underwriter may engage in overallotment, stabilizing
transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create
a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed
a specified maximum price. Syndicate covering or other short-covering transactions involve purchases of the securities, either through
exercise of the option to purchase additional shares or in the open market after the distribution is completed, to cover short positions.
Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short
positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the
dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities
to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions
may be effected on any exchange or over-the-counter market or otherwise.
Any underwriters, dealers or agents that are qualified
market makers on the NYSE American LLC may engage in passive market making transactions in our Common Stock on the NYSE American LLC in
accordance Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement
of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified
as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent
bid for such security; if all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s
bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities
at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.
The specific terms of any lock-up provisions in respect of any given
offering will be described in the applicable prospectus supplement.
The anticipated date of delivery of offered securities
will be set forth in the applicable prospectus supplement relating to each offer.
LEGAL MATTERS
Unless otherwise indicated in the applicable
prospectus supplement, the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon for
us by Blank Rome LLP, New York, New York. Additional legal matters may be passed upon for us or any underwriters, dealers or agents,
by counsel that we will name in the applicable prospectus supplement.
EXPERTS
The consolidated financial statements of iBio
Inc. and Subsidiaries for the two years ended June 30, 2023 have been audited by CohnReznick LLP, independent registered public accounting
firm, as set forth in their report thereon appearing in iBio Inc. and Subsidiaries Annual report on Form 10-K for the year ended June 30, 2023, and incorporated by reference herein. Such consolidated financial statements are incorporated by reference herein in reliance
upon such report, which includes an explanatory paragraph on our ability to continue as a going concern, given on the authority of such
firm as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
This prospectus is part of a registration statement
we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits
to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we
refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any
agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these
securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as
of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale
of the securities offered by this prospectus.
We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at www.sec.gov.
Additional information about iBio, Inc. is contained at our website, www.ibioinc.com. Information on our website is not incorporated
by reference into this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports
are filed with the SEC.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to “incorporate by reference”
information into this prospectus, which means that we can disclose important information to you by referring you to another document filed
separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-35023. The documents
incorporated by reference into this prospectus contain important information that you should read about us.
The following documents are incorporated by reference
into this prospectus:
|
· |
Our Current Reports
on Form 8-K filed with the SEC on August
4, 2023, August
7, 2023, September
21, 2023, October
10, 2023, November
28, 2023, December
6, 2023, December
8, 2023, December
26, 2023, January
19, 2024, February
21, 2024, February
26, 2024, April
1, 2024, May
20, 2024, June 5, 2024,
July 3, 2024, July
9, 2024 and July 26, 2024; and |
|
· |
The description of our Common Stock set forth in: (i) our registration statement on Form 8-A filed with the SEC on March 19, 2014, including any amendments thereto or reports filed for the purposes of updating this description, and (ii) Exhibit 4.10 to our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 filed with the SEC on September 28, 2021. |
We also incorporate by reference into this prospectus
all documents (other than portions of those documents not deemed filed) that are filed by us with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act (Commission File Number 001-35023) after (i) on
or after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness
of such registration statement, and (ii) on or after the date of this prospectus but prior to the termination of the offering (i.e., until
the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this
prospectus forms a part has been withdrawn). These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. Information in such future filings updates and supplements
the information provided in this prospectus.
We will provide to each person, including any
beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents
that are incorporated by reference into this prospectus but not delivered with this prospectus, including exhibits that are specifically
incorporated by reference into such documents. You can request a copy of these filings, at no cost, by writing or telephoning us at the
following address or telephone number:
iBio, Inc.
11750 Sorrento Valley Road, Suite 200
San Diego, CA 92121
(979) 446-0027
Any statement contained in this prospectus or
in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
of this prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed document which also
is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
You may also access these documents, free of charge,
on the SEC’s website at www.sec.gov or on our website at www.ibioinc.com. The information contained in, or that can
be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus or any accompanying prospectus
supplement.
In accordance with Rule 412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement.
You should rely only on information contained
in, or incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with
information different from that contained in this prospectus or incorporated by reference into this prospectus. We are not making offers
to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such
offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation.
![](https://www.sec.gov/Archives/edgar/data/1420720/000110465924086336/tm2418807d1_s3img001.jpg)
Up to $7,350,000
Shares of Common Stock
Prospectus
Chardan Capital Markets, LLC | Craig-Hallum
Capital Group LLC |
August 6, 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024